M&A
M&A
Is the FTC increasing scrutiny amid high M&A levels in health care?
Unprecedented levels of M&A activity are underway and expected to continue in 2021—if the FTC doesn’t step in to block some deals. Here’s what CEOs can expect from FTC enforcement in the Biden administration.
Read More
Consumerism
Deals Report: Early pharma M&A activity points to a busy 2021
Despite the hefty AstraZeneca-Alexion deal, 2020 was considered a slow year in terms of mergers and acquisitions in life sciences. Early activity in the winter signals that 2021 may be a different story.
Read More
Affordability
As investments into ASCs soar, health care leaders must navigate a new landscape
Investing in ASCs is all the rage for health care organizations, according to recent survey data. But enterprises moving into the space must understand it’s not a walk in the park or an easy revenue stream.
Read More
M&A
Deals Report: Examining recent M&A activity in health care
As 2020 comes to an end, M&A activity in the health care sector will see an overall decline in deal volume and value. But while the pandemic has negatively impacted M&A, it hasn’t slowed down activity entirely. Here are some recent deals.
Read More
M&A
Summer Deals Report: Looking at M&A in health care from June to August
In the initial installment of our deals report, Health Evolution looks at the proposed and finalized mergers and acquisitions in the industry that occurred over the preceding three months.
Read MoreCOVID-19 Innovation Guide
The first report in a three-part series on COVID-19 innovation lessons learned by Providence, the pandemic's original ground zero in the U.S. Read the report.
